JMP Securities Reaffirms "Market Outperform" Rating for Taysha Gene Therapies (NASDAQ:TSHA)

JMP Securities reiterated their market outperform rating on shares of Taysha Gene Therapies (NASDAQ:TSHA - Free Report) in a report issued on Tuesday morning,Benzinga reports. The brokerage currently has a $5.00 target price on the stock.

TSHA has been the subject of several other research reports. Chardan Capital reaffirmed a "buy" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, August 13th. Needham & Company LLC reissued a "buy" rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a report on Tuesday. Canaccord Genuity Group dropped their price target on Taysha Gene Therapies from $7.00 to $6.00 and set a "buy" rating for the company in a report on Wednesday, August 14th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $6.38.

Taysha Gene Therapies Stock Up 46.6 %

Shares of Taysha Gene Therapies stock traded up $0.76 on Tuesday, reaching $2.39. 24,419,787 shares of the company were exchanged, compared to its average volume of 2,537,167. The company has a market capitalization of $489.81 million, a price-to-earnings ratio of -10.40 and a beta of 0.44. The company has a current ratio of 5.22, a quick ratio of 5.22 and a debt-to-equity ratio of 0.35. Taysha Gene Therapies has a one year low of $1.19 and a one year high of $4.32. The company has a 50-day moving average of $1.97 and a 200 day moving average of $2.39.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. Taysha Gene Therapies had a negative net margin of 888.18% and a negative return on equity of 168.91%. The firm had revenue of $1.11 million during the quarter, compared to analysts' expectations of $3.62 million. During the same quarter last year, the company posted ($0.38) earnings per share. On average, equities research analysts forecast that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Institutional Investors Weigh In On Taysha Gene Therapies

Large investors have recently bought and sold shares of the company. StemPoint Capital LP acquired a new stake in shares of Taysha Gene Therapies during the 1st quarter valued at $3,122,000. Avoro Capital Advisors LLC grew its holdings in shares of Taysha Gene Therapies by 328.2% during the first quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company's stock worth $53,526,000 after purchasing an additional 14,294,445 shares during the last quarter. Artal Group S.A. lifted its holdings in Taysha Gene Therapies by 0.7% in the first quarter. Artal Group S.A. now owns 3,687,548 shares of the company's stock valued at $10,583,000 after buying an additional 24,444 shares during the period. Quantum Private Wealth LLC grew its holdings in Taysha Gene Therapies by 4.6% during the 2nd quarter. Quantum Private Wealth LLC now owns 730,520 shares of the company's stock worth $1,636,000 after acquiring an additional 32,000 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in shares of Taysha Gene Therapies in the 2nd quarter worth about $1,018,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.